Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity.
Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity.
复制标题
DOI：
10.1161/jaha.122.029282
复制
发表时间：
2023-06-06
影响因子：
5.4
通讯作者：
Gulati, Martha
中科院分区：
文献类型：
--
作者：
Michos, Erin D.;Lopez-Jimenez, Francisco;Gulati, Martha
肥胖仍然是一个主要的公共卫生问题，影响着美国近一半的成年人。心血管疾病（CVD）风险增加和CVD死亡率是肥胖相关的主要并发症，管理指南现在建议将减肥作为超重或肥胖患者一级预防心血管疾病的关键策略。最近证实的一些慢性体重管理药物疗法的疗效可能会鼓励医疗保健专业人员认识到肥胖是一种可治疗的严重慢性疾病，并激励患者在以前的尝试无效或不可持续时重新参与减肥。这篇综述文章总结了与生活方式改变、减肥手术和肥胖治疗中的历史药理学干预相关的益处和挑战，并重点介绍了新的胰高血糖素样肽-1受体激动剂药物治疗肥胖和降低CVD风险的有效性和安全性的现有证据。我们的结论是，现有证据表明，胰高血糖素样肽-1受体激动剂应在临床实践中强烈考虑用于治疗肥胖和降低2型糖尿病患者的CVD风险。如果正在进行的研究证明胰高血糖素样肽-1受体激动剂可有效降低肥胖患者的CVD发作风险，无论2型糖尿病状态如何，它将预示着这种情况下的新治疗模式，现在是医疗保健专业人员更好地认识这些药物的益处的时候了。
Obesity remains a major public health problem, affecting almost half of adults in the United States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity‐related complications, and management guidelines now recommend weight loss as a key strategy for the primary prevention of CVD in patients with overweight or obesity. The recently demonstrated efficacy of some pharmacologic therapies for chronic weight management may encourage health care professionals to recognize obesity as a treatable serious chronic disease and motivate patients to re‐engage with weight loss when previous attempts have been ineffective or unsustainable. This review article summarizes the benefits and challenges associated with lifestyle changes, bariatric surgery, and historical pharmacologic interventions in the treatment of obesity, and focuses on the current evidence for the efficacy and safety of the newer glucagon‐like peptide‐1 receptor agonist medications in the management of obesity and potential reduction of CVD risk. We conclude that the available evidence demonstrates glucagon‐like peptide‐1 receptor agonists should be strongly considered in clinical practice for the treatment of obesity and reduction of CVD risk in people with type 2 diabetes. If ongoing research proves glucagon‐like peptide‐1 receptor agonists to be effective in reducing the risk of CVD onset in patients with obesity, irrespective of type 2 diabetes status, it will herald a new treatment paradigm in this setting, and now is the time for health care professionals to better recognize the benefits of these agents.
影响因子：
5.8
作者：
Ebbert, Jon O.;Elrashidi, Muhamad Y.;Jensen, Michael D.
通讯作者：
Jensen, Michael D.
影响因子：
2.2
作者：
通讯作者：
--